Efficacy Of Injecting Intra-Vitreal Moxifloxacin In Acute Post-Operative Endophthalmitis

Adnan Ahmad1, Mubbashir Rehman1

  • 1Department of Ophthalmology, Nowshera Medical College, Nowshera-Pakistan.

Insights

Intra-vitreal moxifloxacin offers a broad-spectrum alternative for treating post-operative endophthalmitis, showing improved outcomes compared to traditional antibiotics like vancomycin and ceftazidime.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Acute post-operative endophthalmitis is a severe ocular infection often treated with intra-vitreal vancomycin and ceftazidime.
  • Antibiotic resistance poses a challenge, leading to suboptimal treatment responses.

Observation:

  • A 65-year-old male presented with acute vision loss post-cataract surgery, exhibiting signs of endophthalmitis.
  • Clinical examination revealed severe intraocular inflammation, including hypopyon and vitritis.

Findings:

  • Intra-vitreal moxifloxacin (0.5mg/0.2ml) was administered, alongside topical/oral antibiotics and steroids.
  • Visual acuity improved to 6/24, with resolution of intraocular inflammation at 4-week follow-up.

Implications:

  • Intra-vitreal moxifloxacin monotherapy demonstrates efficacy and broad-spectrum coverage for acute post-operative endophthalmitis.
  • Moxifloxacin may be a superior alternative to combined vancomycin and ceftazidime, addressing antibiotic resistance concerns.